Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05434156
Other study ID # ET1001-ELE-101
Secondary ID 2022-000150-29
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 27, 2022
Est. completion date September 2024

Study information

Verified date January 2024
Source Eleusis Therapeutics
Contact Beckley Psytech Ltd
Phone +44 (0)1865 987633
Email Medinfo@beckleypsytech.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).


Description:

This is a 2-part study. Part 1 is a phase I, double-blind, placebo-controlled, randomized study to assess the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) and subjective drug intensity (SDI) of single ascending intravenous (IV) doses of ELE-101 in healthy male and female adult participants. Part 2 is a Phase IIa, open-label study to evaluate a range of pharmacodynamic effects of a single intravenous dose of ELE-101 in patients with depression. Healthy participants will receive either ELE-101 or placebo as an IV infusion in Part 1 and patients with MDD will receive ELE-101 as an IV infusion in Part 2.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date September 2024
Est. primary completion date April 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy male or female participants aged 18 to 65 years, inclusive. - Participants have a body mass index (BMI) of 18 to 35 kg/m2, inclusive. - Participants are able and willing to give written informed consent, adhere to the compliance terms during participation in the study, undergo the examinations and testing set forth in the study Protocol and clearly and reliably communicate their subjective symptoms to the Investigator. - Part 2 Only: Patient has a diagnosis of MDD and is not on antidepressant medication. Exclusion Criteria: - Current, or history (within the last 6 months) of, alcohol or substance use disorder. - Use of pharmacological compounds for psychiatric or neurological conditions acting on the CNS within 30 days or 5 half-lives (whichever is longer) prior to Screening. - Current or clinically relevant history of schizophrenia, psychotic, bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder or panic disorder. - In first-degree relatives, a history of schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder or schizoaffective disorder. - History of a diagnosis of Hallucinogen Persistent Perceptual Disorder (HPPD). - Significant suicide risk. - Other personal circumstances and behavior that is incompatible with establishment of rapport or safe exposure to psilocin, as judged by the Investigator. - Part 1 Only: Ongoing current MDD, or history of MDD within the last year.

Study Design


Intervention

Drug:
ELE-101
ELE-101 solution for intravenous infusion
ELE-101 Placebo
ELE-101 placebo matching solution for intravenous infusion

Locations

Country Name City State
United Kingdom MAC Clinical Research Liverpool
United Kingdom MAC Clinical Research Manchester

Sponsors (1)

Lead Sponsor Collaborator
Eleusis Therapeutics

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Percentage of participants with at least one safety event Safety will be evaluated by the monitoring of adverse events (AEs), vital signs, blood pressure, heart rate, pulse oximetry, electrocardiogram (ECG) evaluations, clinical laboratory assessments, injection site reactions and physical examination findings.
Suicidal ideation and behavior will be evaluated using the Columbia-Suicide Severity Rating Scale (C-SSRS).
Percentage of participants who experience at least one treatment-emergent adverse event (TEAE) will be captured.
Tolerability will be measured using the SDI questionnaires to rate the intensity of the psychedelic experience alongside recordings of anticipated adverse effects such as nausea and headache.
Baseline up to Day 8
Primary Part 2: Subjective Drug Intensity Ratings - The SDI questionnaire will be used to rate the real-time intensity of the psychedelic experience pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: Cmax: Maximum observed plasma concentration for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: Tmax: Time to reach maximum plasma concentration (Cmax) for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: AUCinf: Area under the plasma concentration-time curve from Time 0 to Infinity for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: AUClast: Area under the plasma concentration-time curve from Time 0 to the time of the last quantifiable concentration for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: AUC0-24: Area under the plasma concentration-time curve from Time 0 to 24 hours for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: VZ: volume of distribution during the terminal disposition phase for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: VZss: volume of distribution at steady state for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: Cl: apparent total clearance from plasma for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: MRTinf: mean residence time from Time 0 to Infinity for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: t1/2: Terminal disposition phase half-life for ELE-101 and its metabolites PK parameters in plasma will be calculated for psilocin and its primary metabolites throughout the study pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 1 and 2: Dischargeability: Assessment of subject-discharge readiness The dischargeability evaluation will be based on Investigator judgement after review of participant safety data. post-dose and 24 hours post-dose
Secondary Part 1: The dose related psychoactive effects of ELE-101 as evaluated by a Visual Analogue Scale The Subjective Drug Intensity (SDI) is a Visual Analogue Scale scored from 0-10. pre-dose and at multiple time-points up to 24 hours post-dose
Secondary Part 2: The effects of ELE-101 on the severity of depression evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS) The MADRS is a diagnostic questionnaire with ten items for measuring the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6. The overall score ranges from 0 to 60. Baseline up to Day 29
Secondary Part 2: Percentage of participants with at least one safety event Safety will be evaluated by the monitoring of adverse events (AEs), vital signs, blood pressure, heart rate, pulse oximetry, electrocardiogram (ECG) evaluations, clinical laboratory assessments, injection site reactions and physical examination findings.
Suicidal ideation and behavior will be evaluated using the Columbia-Suicide Severity Rating Scale (C-SSRS).
Percentage of participants who experience at least one treatment-emergent adverse event (TEAE) will be captured.
Tolerability will be measured using the SDI questionnaires to rate the intensity of the psychedelic experience alongside recordings of anticipated adverse effects such as nausea and headache.
Baseline up to Day 29
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A